Bod Science has received ethics approval for a second pharmacokinetics (PK) study that will test the bioavailability of its much-heralded Aqua Phase CBD technology.
Recruitment for the 12 participants is already underway, with the study set to explore the bioavailability in venous blood, which flows from capillary blood vessels to larger veins to the right hand side of the heart. The results are expected by the end of July.
Bod’s initial, 10-participant PK study, which is already underway with results likely next month, is testing the bioavailability of Aqua Phase in capillary blood.
Both studies will see Aqua Phase go head-to-head with CBD in MCT oil.
News of the ethics approval came as Bod revealed that a third study using ultraviolet (UV) analysis showed improved solubility of Aqua Phase CBD compared to standard CBD.
Poor solubility impacts biological absorption, with CBD suspended in MCT oil typically delivering bioavailability of between 6% and 8%.
Bod has previously indicated that Aqua Phase is expected to deliver bioavailability of more than 30% through a methodology which creates a molecule which is “truly soluble”.
Chief executive Jo Patterson said advanced discussions are continuing with potential partners interested in adopting the Aqua Phase technology.
Not only will the increased bioavailability lead to cost savings for patients, it will also be safer, she said.
“We are increasingly confident in the commercial potential of this unique delivery format in numerous global markets,” Patterson said.
“It promises to enable poor solubility medications to become cheaper and safer as a result of lower side effects and less use of the active ingredient required due to the increased solubility.”
“The solubility data… enables us to move forward a number of commercial opportunities in cannabis and non-cannabis medications with increasing confidence.”
